Alberta adds alternative drug after Pfizer pulls Premarin from Canada
Pfizer is discontinuing its Canadian-made menopause drug Premarin while continuing to sell it in the U.S., prompting Alberta to add a substitute to its drug benefit list.
Why it matters
Albertans who relied on Premarin for menopause symptoms will need to switch to a newly listed alternative drug as the original product leaves the Canadian market.
Pfizer has discontinued Premarin vaginal cream for Canadian patients as of early November, citing "business reasons," and plans to pull the Premarin tablet from the Canadian market by June of next year. The drug, used for decades to treat menopausal symptoms like hot flashes, vaginal dryness and osteoporosis prevention, will remain available to patients in the United States.
The active ingredient, conjugated equine estrogen, is collected from pregnant mares at 12 family-owned ranches in Manitoba and Saskatchewan, a supply chain running since the early 1940s. Pfizer Canada spokesperson Sophie Morin said the products became "commercially unsustainable," pointing to manufacturing and supply costs and the pricing and reimbursement environment, though she said pricing alone did not drive the decision. A U.S.-based gynecologist noted the cream sells for roughly C$50 a tube in Canada versus US$400 to $500 in the U.S.
In response, Alberta's Ministry of Health says it is adding an alternative, Estragyn vaginal cream made by Searchlight Pharma, to the province's drug benefit list so patients still have coverage. A ministry spokesperson described the move as temporary for now but said it is intended to become permanent. Quebec and Manitoba already cover the Estragyn alternative, while Ontario currently covers other estrogen products, such as a vaginal ring, tablet and insert, which a menopause specialist says contain different active ingredients and may not suit all patients, particularly for dryness.
Compiled by the Alberta Daily Desk — an AI-written summary of reporting from the credited sources below, produced and reviewed under our editorial policy.